The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer.
F. Andre
Consultant or Advisory Role - Novartis
Honoraria - Novartis
T. D. Bachelot
Consultant or Advisory Role - Novartis
Research Funding - Novartis
M. Campone
No relevant relationships to disclose
F. Dalenc
No relevant relationships to disclose
J. M. Perez-Garcia
No relevant relationships to disclose
S. A. Hurvitz
No relevant relationships to disclose
N. C. Turner
Consultant or Advisory Role - Novartis
Honoraria - Novartis
H. S. Rugo
Research Funding - Novartis
M. M. Shi
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Y. Zhang
Employment or Leadership Position - Novartis
A. C. M. Kay
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
A. J. Yovine
Employment or Leadership Position - Novartis
J. Baselga
Consultant or Advisory Role - Novartis